Skip to content
Health
Link copied to clipboard
Link copied to clipboard

Philly biotech reports serious side effect in patient with lupus

The patient was being treated for lupus and developed a neurological side effect that is a known risk of CAR-T.

The office of Steven Nichtberger, co-founder and CEO of Cabaletta Bio. The company recently announced that a lupus patient taking the drug it's investigating developed a serious side effect.
The office of Steven Nichtberger, co-founder and CEO of Cabaletta Bio. The company recently announced that a lupus patient taking the drug it's investigating developed a serious side effect.Read moreJoseph N. DiStefano (custom credit)